Design of an AI model for predicting antiretroviral resistance in HIV patients: a case study in cameroon

Abstract Antiretroviral (ARV) resistance poses a major challenge for HIV patient management in Cameroon, with resistance prevalence reaching 15% in treatment-naive patients and up to 93.3% among those experiencing therapeutic failure. Resistance detection currently relies on expensive genotypic tests (approximately 165 USD per test – very expensive compared to the cost of living in Cameroon), which are largely inaccessible and performed only at the transition from second- to third-line therapy. Of the 448,911 patients on ARV treatment, approximately 4,500 require annual testing; however, national testing capacity is limited to only 1,000–1,500 tests per year, creating a coverage deficit of 66–78%. This study presents the design and implementation of an artificial intelligence (AI) model to predict ARV resistance in people living with HIV in Cameroon, using routine clinical data and machine learning algorithms. Data from two local sources—the Centre International de Référence Chantal Biya (CIRCB, n = 1,420 patients) and the Étoug-Ébé Electronic Medical Record (EMR, n = 4,982 patients)—were processed and used to train nine machine learning algorithms. XGBoost achieved the best overall performance on the held-out test set ( n = 272): AUC = 0.763 (95% CI: 0.678–0.849), precision 96.3%, recall (sensitivity) 73.6%, specificity 68.2% (95% CI: 47.3–83.7%), negative predictive value 18.5% (95% CI: 11.6–28.3%), and F1-score 0.834. A functional pilot interface (Streamlit) was developed for real-time clinical decision support. Integration into the national EMR system is proposed as a future step to improve therapeutic management and reduce treatment failures. So, AI-based prediction of ARV resistance using routine clinical data is a feasible and cost-effective approach in resource-limited settings. This model could support earlier treatment decisions, reduce reliance on expensive genotypic testing, and improve HIV patient management in Cameroon.

Authors

Institutions

Publication Details

Journal
BMC Family Practice
Published
2026-11-03
DOI
https://doi.org/10.1186/s12875-026-03608-8
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Design of an AI model for predicting antiretroviral resistance in HIV patients: a case study in cameroon

Joseph Fokam, Anne Marie Chana, Bernabé Batchakui, Edith Saounde Temgoua et al.
BMC Family Practice
HIV/AIDS drug development and treatment
article

Design of an AI model for predicting antiretroviral resistance in HIV patients: a case study in cameroon

Joseph Fokam, Anne Marie Chana, Bernabé Batchakui, Edith Saounde Temgoua, Jean Pierre Anguissa Abessolo, Jaurès Styve Kameni Homté, Louis Dieudonné Onguene Zanga
article en

Abstract

Abstract Antiretroviral (ARV) resistance poses a major challenge for HIV patient management in Cameroon, with resistance prevalence reaching 15% in treatment-naive patients and up to 93.3% among those experiencing therapeutic failure. Resistance detection currently relies on expensive genotypic tests (approximately 165 USD per test – very expensive compared to the cost of living in Cameroon), which are largely inaccessible and performed only at the transition from second- to third-line therapy. Of the 448,911 patients on ARV treatment, approximately 4,500 require annual testing; however, national testing capacity is limited to only 1,000–1,500 tests per year, creating a coverage deficit of 66–78%. This study presents the design and implementation of an artificial intelligence (AI) model to predict ARV resistance in people living with HIV in Cameroon, using routine clinical data and machine learning algorithms. Data from two local sources—the Centre International de Référence Chantal Biya (CIRCB, n = 1,420 patients) and the Étoug-Ébé Electronic Medical Record (EMR, n = 4,982 patients)—were processed and used to train nine machine learning algorithms. XGBoost achieved the best overall performance on the held-out test set ( n = 272): AUC = 0.763 (95% CI: 0.678–0.849), precision 96.3%, recall (sensitivity) 73.6%, specificity 68.2% (95% CI: 47.3–83.7%), negative predictive value 18.5% (95% CI: 11.6–28.3%), and F1-score 0.834. A functional pilot interface (Streamlit) was developed for real-time clinical decision support. Integration into the national EMR system is proposed as a future step to improve therapeutic management and reduce treatment failures. So, AI-based prediction of ARV resistance using routine clinical data is a feasible and cost-effective approach in resource-limited settings. This model could support earlier treatment decisions, reduce reliance on expensive genotypic testing, and improve HIV patient management in Cameroon.

BMC Family Practice
Université de Yaoundé I (CM), Centre International De Reference Chantal Biya (CM), National Advanced School of Public Works (CM)
Openalex Percentile: Top 14%
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon